Distinguishing Perception from Evidence in Psychiatrists’ Attitudes Toward Second-Generation Long-Acting Injectable Antipsychotics [Letter]
Neuropsychiatric Disease and Treatment · 2026-07 · Volume 22 · 1-2
DOI: 10.2147/ndt.s638774 ↗Kurz gefasst
Leserbrief in der Zeitschrift Neuropsychiatric Disease and Treatment, 2026-07. Verfasst von Yoshiyo Oguchi. Beteiligte Einrichtung: Department of Neuropsychiatry, Teikyo University Mizonokuchi Hospital, Kawasaki, Kanagawa, Japan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost", in which 80 Romanian psychiatrists rated the four available second-generation long-acting injectable antipsychotics (SG-LAIs) across a range of domains. 1 Aripiprazole was rated most favorably on nearly every domain and in terms of overall preference.Lack of patient trust, limited hospital supply, and inexperience were listed among the principal barriers to SG-LAI prescribing. 1 This is a welcome addition to the sparse literature on prescriber attitudes in Central and Eastern Europe, and I would like to offer three observations that may help to further frame the study's findings, as well as suggest some potential future directions worth pursuing in the field.The study measured what Romanian clinicians believed regarding the effectiveness, safety, and cost of these agents, rather than their properties themselves.As the authors stated, no patient-level data were collected.1 This distinction is crucial when interpreting the study.Cost is the clearest case: in a system that, as the authors describe, fully reimburses LAIs for insured patients, a rated cost does not reflect real economic burden and is best interpreted as simply another opinion.Understood this way, as a study of perception rather than of the drugs themselves, the survey gains importance rather than losing it.Once reimbursement and supply no longer determine which agent a patient receives, the remaining variation in prescriptions falls largely to each clinician's individual discretion.This is precisely what the survey in question captured.It may be worthwhile to state this explicitly when interpreting the study, so that the survey's thorough attitudinal data are considered as such, rather than as comparative clinical or pharmacoeconomic evidence.The efficacy ratings illustrate the same point.Aripiprazole was rated clearly the most effective agent; however, the maintenance network meta-analysis the authors cited found no clear differences in efficacy among these drugs, and the authors themselves described the efficacy levels of the studied SG-LAIs as broadly comparable.1,2 When the available evidence draws no efficacy-related distinctions, but the ratings draw a clear one, the most conservative interpretation is that the perceived efficacy score measured something other than efficacy.This is most likely the tolerability, ease of administration, and freedom from post-injection monitoring that genuinely set aripiprazole apart.Consistent with this, aripiprazole was rated most favorably on almost every attribute concurrently, suggesting a single overall impression that biased respondents' individual ratings, rather than an independent appraisal of each attribute.The same tolerability-led ordering appears in the 2025 Japanese expert consensus, in which the D2 partial agonists aripiprazole and brexpiprazole scored higher on tolerability, rather than on any efficacy-related advantages.3 The fact that prescriber communities from regions as disparate as Romania and Japan converged on the same agent, and for similar reasons, argues for a shared Treatment 2026:22 638774 1 Neuropsychiatric Disease and
Autor:innen und Institutionen
- Department of Neuropsychiatry, Teikyo University Mizonokuchi Hospital, Kawasaki, Kanagawa, Japan.
ORCID-Profile: Yoshiyo Oguchi
Zitieren
APA
Oguchi, Y. (2026). Distinguishing Perception from Evidence in Psychiatrists’ Attitudes Toward Second-Generation Long-Acting Injectable Antipsychotics [Letter]. Neuropsychiatric Disease and Treatment, Volume 22, 1-2. https://doi.org/10.2147/ndt.s638774
Vancouver
Oguchi Y. Distinguishing Perception from Evidence in Psychiatrists’ Attitudes Toward Second-Generation Long-Acting Injectable Antipsychotics [Letter]. Neuropsychiatric Disease and Treatment. 2026;Volume 22:1-2. doi:10.2147/ndt.s638774
BibTeX
@article{Oguchi2026,
author = {Oguchi, Yoshiyo},
title = {Distinguishing Perception from Evidence in Psychiatrists’ Attitudes Toward Second-Generation Long-Acting Injectable Antipsychotics [Letter]},
journal = {Neuropsychiatric Disease and Treatment},
year = {2026},
volume = {Volume 22},
pages = {1--2},
doi = {10.2147/ndt.s638774}
}
EUVIMED